Drug intelligence / Profile preview

SIS009

Development stage: Unknown
Lead developer: Nanjing Sanhome Pharmaceutical
Administration: Parenteral

Overview

SIS009 is an investigational therapeutic candidate being developed by Nanjing Sanhome Pharmaceutical for the treatment of solid tumors. It is currently in Phase 2 clinical development. Detailed molecular characteristics, target specificity, and mechanism of action have not been publicly disclosed by the developer.

Targets

FCGRT (Neonatal crystallizable fragment receptor)CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on SIS009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIS009.

Explore the full profile